Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma.

Kaminski, Mark; Zasadny, Kenneth R.; Francis, I.R.; Fenner, Matthias; Ross, Charles W.; Milik, A. W.; Estes, Judith; Tuck, Melissa; Regan, Denise; Fisher, Susan J.; Glenn, Stephan D.; Wahl, Richard L.

doi:10.1200/jco.1996.14.7.1974

Cited by 354 publications

(154 citation statements)

References 0 publications

Supporting

Mentioning

148

Contrasting

Unclassified

Order By: Relevance

“…A later report of 34 patients with mixed histologies confirmed the initial promising activity and documented the durability of some remissions (Kaminski et al, 1996). Near complete depletion of the B-cell pool was observed, although serum immunoglobulin levels remained unchanged.…”

Section: Tositumomabmentioning

confidence: 68%

“…This report updated previous efficacy reports (Kaminski et al, 1996;Wahl et al, 1998) of the initial phase I/II and included the first long-term follow-up data. Once again, this was a heavily pretreated population (66% of patients having had Xfour prior therapies), and many had poor risk features.…”

Section: Tositumomabmentioning

confidence: 72%

“…From this the I 131 activity of the for the total body dose may be derived (Wahl, 2003). The maximum tolerated whole body dose was established as 75 cGy in the phase I study, limited by haematological toxicity, with attenuation to 65 cGy in those patients with relative thrombocytopenia (platelets 100-149 Â 10 9 /l) (Kaminski et al, 1993(Kaminski et al, , 1996. The therapeutic step is performed at days 8-14, where a further infusion of unlabelled tositumomab is followed by the patient-specific whole body dose of I 131 tositumomab.…”

Section: Tositumomabmentioning

confidence: 99%

See 2 more Smart Citations

Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I131 tositumomab

Davies

2007

Oncogene

View full text Add to dashboard Cite

Radioimmunotherapy, targeting the CD20 antigen, in B-cell lymphoma has clearly demonstrated efficacy and tolerability over the preceding 15 years. As a result, two products are available with Food and Drug Administration approval for marketing -Y 90 ibritumomab tiuxetan and I 131 tositumomab, given as the Zevalin and Bexxar therapeutic regimens, respectively. Both demonstrate high-response rates and durability of remission in the relapsed/refractory disease setting. Data are emerging regarding their utility as initial therapy, and furthermore, they are been investigated for use sequentially with chemotherapy, and in the myeloablative setting. As yet however, how to best use these agents in the clinical disease course remains uncertain.

show abstract

Section: Tositumomabmentioning

confidence: 68%

Section: Tositumomabmentioning

confidence: 72%

Section: Tositumomabmentioning

confidence: 99%

See 1 more Smart Citation

Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I131 tositumomab

Davies

2007

Oncogene

View full text Add to dashboard Cite

show abstract

“…88 High RRs have been seen in both newly diagnosed patients 89 as well as those previously extensively treated with chemotherapy. 90,91 Trials exploring the use of two radioimmunoconjugates, ie iodine-131 ( 131 I)-tositumomab (Bexxar) and yttrium-90 ( 90 Y)-ibritumomab tiuxetan (Zevalin) will be reviewed here.…”

Section: Conjugated Anti-cd20 Mabs In Lymphoma Therapymentioning

confidence: 99%

Anti-CD20-based therapy of B cell lymphoma: state of the art

et al. 2002

View full text Add to dashboard Cite

Over the last 5 years, studies applying the chimeric anti-CD20 MAb have renewed enthusiasm and triggered world-wide application of anti-CD20 MAb-based therapies in B cell non-Hodgkin's lymphoma (NHL). Native chimeric anti-CD20 and isotopelabeled murine anti-CD20 MAbs are currently employed with encouraging results as monotherapy or in combination with conventional chemotherapy and in consolidation of remission after treatments with curative intent (ie after/ in combination with high-dose chemotherapy and hematopoietic stem cell rescue). On the available experience, anti-CD20 MAb-based therapeutic strategies will be increasingly integrated in the treatment of B cell NHL and related malignancies.

show abstract

“…Radiolabeled antibodies may also be more effective than their unlabeled counterparts because they do not have to reach every malignant cell to be effective. 6 Depending on the radioisotope used, the radiation can have an effect over 1 to 5 mm or more. Studies with 131 I-radiolabeled B cell antibodies indicate that significant dose escalation with radioimmunoconjugates is clearly possible with autologous stem cell transplantation.…”

Section: Radioimmunoconjugated Mabmentioning

confidence: 99%

Monoclonal antibodies and autologous stem cell transplantation for lymphoma

Flinn¹,

Lazarus

2001

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:The introduction of monoclonal antibodies into the clinic has paved the way for new approaches to stem cell transplantation for patients with lymphoma. These approaches include the development of new high-dose regimens with radiolabeled antibodies, in vivo purging techniques with the unlabeled antibodies, and posttransplant adjuvant immunotherapy. Numerous trials have demonstrated the feasibility of these approaches. However, questions remain regarding the application of these antibodies including the ultimate efficacy. The recent results of the incorporation of monoclonal antibodies into stem cell transplantation and current research directions are reviewed. Bone Marrow Transplantation (2001) 27, 565-569. Keywords: transplantation; monoclonal antibody; lymphoma In 1975, Köhler and Milstein first reported a reproducible technique for inducing and large-scale production of monoclonal antibodies (MAB), agents which bind to specific antigens on cell surfaces. 1 This publication met with significant optimism as it described a new way to specifically target and destroy malignant cells using murine MAB. In 1979 the first attempt at MAB therapy was undertaken. 2 Unfortunately, however, the early clinical trials were not as successful as originally anticipated. Obstacles included the immunogenicity of the murine MAB which shortened the serum half-life and prevented repeat dosing, inadequate fixation of human complement, and the inability to fully activate host antibody-dependent cellular cytotoxicity (ADCC). 3,4 These obstacles subsequently were overcome by methods of 'humanization' of the MAB which retain the antigen-binding portion of the MAB contained within the murine variable or hypervariable regions and replace the remainder of the antibody with the human counterparts. This 'humanization' of product decreased the immuno- genicity and thus permitted multiple dosing, increased the serum half-life and allowed for the fixation of complement and activation of ADCC. In addition, significant insight has been gained into what constitutes an appropriate target. As most lymphomas are of B cell origin, B cell antigens such as CD20 and CD22 have become popular choices. These advances have resulted in MAB becoming effective tools alone or in combination with chemotherapy frequently employed in the treatment of lymphoma. 5 Many MAB products presently are approved for clinical use or in various stages of approval, and include radioimmunoconjugates with various isotopes as well as 'naked' antibodies (Table 1). The development of murine and humanized MAB has opened the way for several improvements in the peripheral blood and marrow transplantation of lymphoma, which will be reviewed herein. Radioimmunoconjugated MABAs outlined above, the clinical utility of murine monoclonal antibodies was limited by the short half-life, immunogenicity, and difficulty with fixing complement and effecting ADCC. An alternative approach is to attach a source of radiation emission to the antibody as a way of giving targeted radiation therapy....

show abstract

Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma.

Abstract: Nonmyeloablative radioimmunotherapy with 131I-anti-B1 is associated with a high rate of durable remissions in patients with B-cell lymphoma refractory to chemotherapy.

Cited by 354 publications

References 0 publications

Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I131 tositumomab

Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I131 tositumomab

Anti-CD20-based therapy of B cell lymphoma: state of the art

Monoclonal antibodies and autologous stem cell transplantation for lymphoma

Contact Info

Product

Resources

About